Bio-Techne to acquire Namocell

By staff writers

June 22, 2022 -- Bio-Techne has reached a deal to acquire Namocell, a Mountain View, CA-based single cell selection and sorting technology provider.

Namocell's instrument portfolio includes Pala, a two-laser system with up to 11 fluorescent detection channels, and Hana, a single-laser system with two fluorescent detection channels.

Bio-Techne noted that single cell selection and sorting is a critical technology in biotherapeutic and diagnostic workflows, including cell and gene therapy development and commercialization, cell engineering, cell line development, single cell genomics, antibody discovery, synthetic biology, and rare cell isolation.

Financial and other terms of the deal have not been disclosed.

The acquisition is expected to close in the first quarter of Bio-Techne's fiscal year 2023.

Bio-Techne, Nonangen enter into agreement for Oncuria
Bio-Techne and Nonagen Bioscience recently entered into an agreement for Bio-Techne's R&D Systems unit to exclusively manufacture Nonagen’s Oncuria bladder...
Bio-Techne touts study with ExoDx prostate test
Bio-Techne is touting a new clinical study that indicates that its exosome-based, noninvasive urine prostate test, ExoDx Prostate test (EPI), correlates...
Bio-Techne launches multiplex spatial genomics assay
Bio-Techne has expanded its RNAscope in situ hybridization technology portfolio with the release of the new RNAscope HiPlex V2 assay for formalin-fixed,...
Bio-Techne teams up with Leica to bring RNAscope to Europe
Global life sciences firm Bio-Techne and pathology workflow software developer Leica Biosystems have launched Bio-Techne's RNAscope in situ hybridization...
Bio-Techne's prostate cancer test lands FDA breakthrough status
Bio-Techne's ExoDx Prostate IntelliScore liquid biopsy test for spotting aggressive prostate cancers has received the U.S. Food and Drug Administration's...

Copyright © 2022

Last Updated mp 6/22/2022 12:53:28 PM